(NASDAQ GM: IVVD)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Invivyd, Inc. ("Invivyd" or the "Company") on behalf of stockholders. A class action complaint has been filed against Invivyd. Invivyd was formed in June 2020 to develop drugs for the treatment and prevention of COVID-19 and future coronavirus outbreaks. The Company was focused on developing ADG20, an investigational monoclonal antibody treatment for COVID-19. In September 2022, Adagio Therapeutics, Inc. announced that it was changing its corporate name to Invivyd. The complaint alleges that defendants failed to disclose that: (i) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim ADG20 was effective against the Omicron variant were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (ii) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (iii) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.